JD had a great post over on Stockhouse the other day about Voyager's recent deal with Abbvie. AAVs have a ton of potential for sure, but they do have limitations. AAVs are versatile, but are not the only trick in the gene-targeted therapy toolbox. I wrote a post on gene targeted therapies over on the Resverlogix hub that touches on AAVs and other stuff. It might be of interest here too on the Bioasis hub.

BearDownAZ